Entries by Maren Kühr

Single-Use Simplicity under control

Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors. Furthermore, using them together with a powerful bioprocess controller like the BioFlo® 320 enables precise cell culture parameter control and seamless process transition to up to 40 L of working volume.

Reinforcement for Supervisory Board

Dr Trevor Hawkins, entrepreneur, scientist, and leader with experience in global healthcare companies, has joined the Supervisory Board of Polish molecular diagnostic company Genomtec S.A.

Curious2024 – Future Insight Conference

From July 10th to 11th, the multidisciplinary Curious2024 – Future Insight™️ Conference is bringing together some of the world’s brightest scientists, including several Nobel laureates, and the most accomplished innovators to present their work and explore the future of science and technology, solving the challenges of today and enabling the dreams of a better tomorrow.

Faron Pharmaceuticals with Interim CFO

Finnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.

Biology as Software

At a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will be driven by data, but also will be personalised. Mark Kotter elaborates here in more detail what is needed to unlock a healthcare of tomorrow.

SMEs suffer from CTIS

Born with the aim of harmonising the application, evaluation, and supervision process of clinical trials conducted in EU countries, there is much room for improvement for the Clinical Trial Information System CTIS, particularly with regard to SMEs and translational researchers.

Are there bright times for biotech IPOs ahead?

Despite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.